.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
US Department of Justice
Argus Health
Teva
Healthtrust
Farmers Insurance
UBS
Fish and Richardson
McKinsey
Julphar

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022488

« Back to Dashboard

NDA 022488 describes LYRICA, which is a drug marketed by Pf Prism Cv and Pfizer Inc and is included in three NDAs. It is available from eleven suppliers. There are five patents protecting this drug and two Paragraph IV challenges. Additional details are available on the LYRICA profile page.

The generic ingredient in LYRICA is pregabalin. There are thirty-seven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the pregabalin profile page.

Summary for 022488

Tradename:1
Applicant:1
Ingredient:1
Patents:3
Therapeutic Class:Anticonvulsants
Formulation / Manufacturing:see details

Medical Subject Heading (MeSH) Categories for 022488

Suppliers and Packaging for NDA: 022488

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LYRICA pregabalin SOLUTION;ORAL 022488 NDA Parke-Davis Div of Pfizer Inc 0071-1020 0071-1020-01 473 mL in 1 BOTTLE (0071-1020-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength20MG/ML
Approval Date:Jan 4, 2010TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 22, 2019
Regulatory Exclusivity Use:
Patent:► SubscribePatent Expiration:Dec 30, 2018Product Flag?Substance Flag?Delist Request?Y
Patented Use:MANAGEMENT OF FIBROMYALGIA
Patent:► SubscribePatent Expiration:Dec 30, 2018Product Flag?Substance Flag?Delist Request?Y
Patented Use:TREATMENT OF PAIN

Expired Orange Book Patents for NDA: 022488

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism CvLYRICApregabalinSOLUTION;ORAL022488-001Jan 4, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Merck
Julphar
Covington
McKinsey
Harvard Business School
Farmers Insurance
Baxter
Express Scripts
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot